17
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis

, , , , , , , , & show all
Pages 24-27 | Received 11 Aug 2006, Accepted 27 Sep 2006, Published online: 02 Jan 2014

References

  • Anderson R. The orthopedic management of rheumatoid arthritis. Arthritis Care Res 1996;9:23–8.
  • Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719–24.
  • Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxf). 2005;44:157–63.
  • Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic effi cacy of multiple intravenous infusions of anti-tumor necrosis factor � monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
  • Rosandich PA, Kelley JT 3rd, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifi ers. Curr Opin Rheumatol 2004;16:192–8.
  • Mooney DP, O'Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. Ann Surg 1990;211:124–9.
  • Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infl iximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.
  • Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infl iximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.
  • Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffi ng V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;15;55:333–7.
  • Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with infl ammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005;64:650–1.
  • Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005;64:1378–9.
  • Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331–5.
  • Nishimura K, Wakimoto N, Sasahara J, Yanagisawa C, Eda F, Nishino J, et al. No change of infl iximab levels in stored blood for preoperative autologous blood donation: a preliminary report. Mod Rheumatol 2005;15:302–4.
  • Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15–25.
  • Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7: 251–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.